HIV Infection
Research on HIV infection and antiretroviral therapy. Studies evaluate viral load suppression, CD4 count improvement, treatment-experienced patients, and prevention of disease progression to AIDS.
Quick Answer
What it is
Research on HIV infection and antiretroviral therapy. Studies evaluate viral load suppression, CD4 count improvement, treatment-experienced patients, and prevention of disease progression to AIDS.
Key findings
- Grade A: Viral Load Reduction (Enfuvirtide (Fuzeon))
- Grade A: CD4 Count Improvement (Enfuvirtide (Fuzeon))
- Grade A: Treatment-Experienced Efficacy (Enfuvirtide (Fuzeon))
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: HIV Infection
- Supplements Studied:1
1 supps · 5 outcomes
Detailed Outcomes
A
Viral Load Reduction
Phase III: Superior virological activity vs optimized background regimen alone at 24 weeks in treatment-experienced patients.
large↓Improves
A
CD4 Count Improvement
Significant immunological improvement demonstrated in pivotal Phase III trials (TORO-1 and TORO-2).
moderate↑Improves
A
Treatment-Experienced Efficacy
Effective in patients with documented resistance to NRTIs, NNRTIs, and PIs. Valuable rescue therapy option.
large↑Improves
A
Viral Suppression Rate
Higher proportion achieving viral suppression when added to optimized background therapy in clinical trials.
moderate↑Improves
A
Time to Treatment Failure
Prolonged time to virologic failure compared to control arm in Phase III studies.
moderate↑Improves